首页> 外文期刊>Clinical drug investigation >Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs
【24h】

Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs

机译:处方药价格悖论:加拿大在线药房的成本分析与美国前100名药物的Medicare受益人

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background and objectives Despite the introduction of Medicare Part D (MPD) and 2012 Affordable Care Act (ACA), patients have a cost burden due to increases in drug prices. To overcome cost barriers, some patients purchase their medications from Canadian online pharmacies as Canadian prescription drug prices are believed to be lower than US prescription drug prices. The objective of this study was to determine which top 100 Medicare drugs can be imported to the USA legally, and to determine which type of prescription drug would be more beneficial to be purchased from Canadian online pharmacies. Moreover, we also deemed it important to compare MPD beneficiary annual expenses with expenses patients would have when obtaining their prescriptions from Canadian online pharmacies. Methods We conducted a cost analysis from a patient perspective. A list of the top 100 Medicare drugs was compiled and information on drug prices was collected from three Canadian online pharmacies and four MPD plans in Virginia. The annual cost of each Medicare drug and percent change between Canadian online pharmacies and MPD were compared. Results A total of 78 drugs from the top 100 Medicare drugs were included in the final analysis. Seventy-six prescription drugs (97.4%) that could be purchased from Canadian online pharmacies showed a significantly lower average drug price percent change of ?72.71% ( P Conclusion The majority of prescription drugs can be purchased at lower prices from Canadian online pharmacies when compared to Medicare beneficiaries’ potential expenses. Purchasing medications from Canadian online pharmacies may be a viable option to address cost barriers.
机译:摘要背景和目标尽管介绍了Medicare D部分(MPD)和2012年经济实惠的护理法案(ACA),患者由于药物价格的增加而产生成本负担。为了克服成本障碍,一些患者从加拿大在线药店购买他们的药物,因为加拿大处方药价格被认为低于美国处方药价格。本研究的目的是确定哪种前100名医疗保障药物可以合法地进口到美国,并确定哪种类型的处方药将从加拿大在线药剂中购买更有利。此外,我们还认为将MPD受益人每年费用与费用患者进行比较,在获得加拿大在线药店的处方时将有。方法我们从患者的角度进行了成本分析。编制了100位Medicare毒品的列表,并从三个加拿大在线药房和弗吉尼亚州的四个MPD计划收集了药品价格的信息。比较了每种药房药物的年费和加拿大在线药房和MPD之间的变化百分比。结果最终分析中,共有78名来自前100名医疗保险药物的药物。可以从加拿大在线药房购买的七十六处方药(97.4%)显示出较低的平均药物价格百分比百分比?72.71%(P结论中的大多数处方药可以在加拿大在线药房的较低价格上购买Medicare受益人的潜在费用。从加拿大在线药店购买药物可能是解决成本障碍的可行选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号